Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Aug 20, 2009

Premium

Title: Modified Gene-Silencing RNA and Uses Thereof

Number: 7,576,262

Filed: March 12, 2003

Lead Inventor: Ming-Bo Wang, Commonwealth Scientific and Industrial Research Organization

The patent, its abstract states, claims “methods and means for efficiently down-regulating the expression of any gene of interest in eukaryotic cells and organisms. … To this end, the invention provides modified antisense and sense RNA molecules, chimeric genes encoding such modified antisense or sense RNA molecules, and eukaryotic organisms such as plants, animals or fungi, yeast or molds, comprising the modified antisense and/or sense RNA molecules or the encoding chimeric genes.”


Title: siRNA Targeting KRAS

Number: 7,576,197

Filed: Dec. 9, 2008

Lead Inventor: Anastasia Khvorova Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs directed to silencing KRAS, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes.”


Title: siRNA Targeting Transducin Beta-Like 3

Number: 7,576,196

Filed: Oct. 14, 2008

Lead Inventor: Anastasia Khvorova Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TBL3.”


Title: siRNA-Mediated Gene-Silencing Technology to Inhibit Tyrosinase and Reduce Pigmentation

Number: 20090202458

Filed: Jan. 29, 2009

Lead Inventor: Ralph Binetti, Avon

The invention, the patent application’s abstract states, “describes compositions and methods for treating, preventing, and improving hyperpigmentation or other unwanted pigmentation of the skin, or other unwanted skin condition such as age spots, aged skin, skin discoloration, etc., wherein the compositions include siRNA gene-silencing oligomers specific for tyrosinase. The compositions are used to treat a broad variety of pigmentation conditions, and are preferably applied to the skin or are delivered by directed means to a site in need thereof.”


Title: miR-150 for the Treatment of Blood Disorders

Number: 20090202493

Filed: Jan. 30, 2009

Lead Inventor: Jun Lu, Yale University

“The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia, [by] increasing miR-150 expression or inhibiting miR-150 in progenitor cells,” the patent application’s abstract states.


Title: Method for Treating Cancer Using Anti-Wnt2 Monoclonal Antibodies and siRNA

Number: 20090202539

Filed: Jan. 30, 2009

Lead Inventor: Liang You, University of California, San Francisco

“This invention relates to methods of inhibiting the growth of cells, in particular cancer cells, that over-express Wnt2,” the patent application’s abstract states. “The methods comprise contacting the cell with an agent that binds to Wnt2 mRNA or Wnt2 protein, [and] interferes with Wnt2 signaling or inhibits binding of the Wnt2 protein to another protein, such as a Frizzled receptor.”


Title: Gene Therapy for Cancer Using Small Interfering RNA Specific to ANT2 and a Method to Overcome Tolerance to Anti-Tumor Agent

Number: 20090202623

Filed: April 11, 2007 PCT Filed: April 11, 2007

Lead Inventor: Chul-Woo Kim, Seoul National University College of
Medicine

The invention, the patent application’s abstract states, “relates to a small interfering RNA suppressing the expression of [the] adenine nucleotide translocator 2 gene and an anti-cancer agent containing the same. Particularly, the invention relates to ANT2 siRNA comprising a sense sequence selected from the nucleotide sequences of ANT2 mRNA, a hairpin loop sequence, and an antisense sequence binding complementarily to the said sense sequence, and an anti-cancer agent containing the same.

“ANT2 siRNA of the … invention inhibits the expression of ANT2 gene, suggesting that it inhibits the growth of cancer cells exhibiting high level of ANT2,” the abstract notes. “Therefore, ANT2 siRNA of the invention can be effectively used for gene therapy for cancer treatment and further prevents the anti-cancer effect from decreasing by anti-cancer drug resistance of cancer cells.”


Title: Compositions and Methods for RNA Interference with Sialidase Expression and Uses Thereof

Number: 20090203055

Filed: April 18, 2006 PCT Filed: April 18, 2006

Lead Inventor: Frederyk Ngantung, Massachusetts Institute of Technology

The invention, the patent application’s abstract states, “provides RNAi agents targeted to sialidase. The RNAi agents include siRNA, shRNA, and expression vectors that comprise a template for transcription of an siRNA or shRNA.

“The invention further provides cells and cell lines that comprise an RNAi agent targeted to sialidase,” the abstract adds. “The cells and cell lines exhibit reduced sialidase activity relative to control cells that do not comprise an RNAi agent targeted to sialidase. Certain of the cell lines stably express the RNAi agent.

“The invention further provides methods of producing the cells and cell lines, [as well as] … methods for producing a glycoprotein in cells that comprise an RNAi agent targeted to sialidase,” it states. “The glycoproteins exhibit an improved sialic acid profile relative to glycoproteins produced by cells that do not comprise an RNAi agent targeted to sialidase. The invention further provides glycoproteins, e.g., therapeutic glycoproteins, produced in the cells.”


Title: Nucleic-Acid Reagents for Down-Regulating H19 and Methods of Using [the] Same

Number: 20090203121

Filed: Jan. 16, 2008

Lead Inventor: Avraham Hochberg, Hebrew University of Jerusalem

The patent application, its abstract states, claims “isolated oligonucleotides capable of down-regulating H19 mRNA in cancer cells … as well as pharmaceutical compositions that include the oligonucleotides and methods of treatment of cancer using them. Methods of treating cancer comprising administering agents capable of down-regulating H19 mRNA in combination with an additional anti-cancer treatment are further disclosed.”


Title: Glycoconjugates of RNA Interference Agents

Number: 20090203135

Filed: April 23, 2008

Lead Inventor: Andrea Forst, Alnylam Pharmaceuticals

The invention, the patent application’s abstract states, “relates to agents, compositions, and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression-inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.”


Title: Small Interfering RNAs Targeting Feline Herpes Virus

Number: 20090203138

Filed: Feb. 12, 2009

Lead Inventor: Stephen Kania, University of Tennessee

The patent application, its abstract states, “provides polynucleotides, compositions thereof, and methods of treating feline herpes virus infections. In certain embodiments, the polynucleotides and compositions thereof can be used to reduce replication of feline herpes simplex virus 1 in vivo and/or in vitro.”


Title: Generation of Tumor-Free Stem-Like Pluripotent Cells Using Inducible Recombinant RNA Agents

Number: 20090203141

Filed: Jan. 8, 2009

Lead Inventor: Shi-Lung Lin, University of Southern California

The invention “generally relates to a method for developing, generating, and selecting tumor-free embryonic stem-like pluripotent cells using electroporation delivery of an inducible tumor suppressor miR-302 agent into mammalian cells,” the patent application’s abstract states. “More particularly, the … invention relates to a method and composition for generating a Tet-on/off recombinant transgene capable of expressing a manually re-designed miR-302 microRNA/shRNA agent under the control of doxycyclin in human somatic/cancer cells, and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.”


Title: Retrotransposon Inhibition in Therapy

Number: 20090203892

Filed: Dec. 30, 2005 PCT Filed: Dec. 30, 2005

Lead Inventor: Enrico Garaci, Sapienza University of Rome

“RNA interference is useful in the treatment of cancerous lesions, wherein the RNA recognizes a portion of at least one LINE-I repeat element,” according to the patent application’s abstract.


Title: Compositions and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases

Number: 20090203894

Filed: Feb. 8, 2008

Lead Inventor: Yijia Liu, Intradigm

The invention, the patent application’s abstract states, comprises “compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference are provided,” the abstract adds.

“The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists,” it notes. “The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.”


Title: siRNA Targeting Cyclin-Dependent Kinase 4

Number: 20090203895

Filed: April 8, 2009

Lead Inventor: Anastasia Khvorova Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing for cyclin-dependent kinase 4 is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.